Cover Image
市場調查報告書

乳癌 (HR+/HER2-) :流行病學·基於患者之市場預測,治療流程,上市藥·開發平台藥物分析

Breast cancer: HR+/HER2-: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365188
出版日期 內容資訊 英文 273 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
乳癌 (HR+/HER2-) :流行病學·基於患者之市場預測,治療流程,上市藥·開發平台藥物分析 Breast cancer: HR+/HER2-: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年04月01日 內容資訊: 英文 273 Pages
簡介

本報告提供乳癌 (HR+/HER2-) 治療藥市場相關調查分析,市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:乳癌 (HR+/HER2-)

  • 摘要整理
  • 市場概要·趨勢
  • 市場定義·手法
  • Abemaciclib
  • Afinitor (everolimus)
  • Alpelisib
  • Avastin (bevacizumab)
  • Buparlisib
  • Entinostat
  • Faslodex (fulvestrant)
  • Halaven (eribulin mesylate)
  • Ibrance (palbociclib)
  • Ixempra (ixabepilone)
  • Lynparza (olaparib)
  • Niraparib
  • Ribociclib
  • Talazoparib
  • Taselisib
  • Veliparib
  • 1次調查手法

治療:乳癌 (HR+/HER2-)

  • 摘要整理
  • 1次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢
  • 未滿足需求

流行病學:乳癌 (HR+/HER2-)

  • 摘要整理
  • 疾病的背景
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優點·缺點

上市藥:乳癌 (HR+/HER2-)

  • 摘要整理
  • 產品概要
  • 產品簡介:Afinitor
  • 產品簡介:Avastin
  • 產品簡介:Faslodex
  • 產品簡介:Halaven
  • 產品簡介:Ibrance
  • 產品簡介:Ixempra

開發平台:乳癌 (HR+/HER2-)

  • 摘要整理
  • 臨床實驗平台概要
  • 標靶藥物簡介
  • 產品簡介 (後期) :Lynparza
  • 產品簡介 (後期) :abemaciclib
  • 產品簡介 (後期) :alpelisib
  • 產品簡介 (後期) :buparlisib
  • 產品簡介 (後期) :entinostat
  • 產品簡介 (後期) :niraparib
  • 產品簡介 (後期) :ribociclib
  • 產品簡介 (後期) :talazoparib
  • 產品簡介 (後期) :taselisib
  • 產品簡介 (後期) :veliparib

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC13425

Ibrance's continued uptake and the approvals of several pipeline therapies will drive the growth of the HR+/HER2- breast cancer market.

This report addresses the following questions:

  • Which branded therapies will have the largest impact on the HR+/HER2- breast cancer market?
  • What is the overall market potential for first-in-class product Ibrance?
  • How will competing CDK4/6 inhibitors ribociclib and abemaciclib fare following the earlier launch of Ibrance?
  • How will PI3K inhibitors alpelisib, buparlisib, and taselisib be positioned in the market?
  • When will generic and biosimilar therapies enter the market and what impact will they have on revenues?

TABLE OF CONTENTS

FORECAST: HR+/HER2- BREAST CANCER

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Abemaciclib
  • 5. Afinitor (everolimus)
  • 6. Alpelisib
  • 7. Avastin (bevacizumab)
  • 8. Buparlisib
  • 9. Entinostat
  • 10. Faslodex (fulvestrant)
  • 11. Halaven (eribulin mesylate)
  • 12. Ibrance (palbociclib)
  • 13. Ixempra (ixabepilone)
  • 14. Lynparza (olaparib)
  • 15. Niraparib
  • 16. Ribociclib
  • 17. Talazoparib
  • 18. Taselisib
  • 19. Veliparib
  • 20. Primary Research Methodology

TREATMENT: HR+/HER2- BREAST CANCER

  • 21. Executive Summary
  • 22. Primary Research Methodology
  • 23. Disease Definition and Diagnosis
  • 24. Patient Segmentation
  • 25. Country Treatment Trees
  • 26. Current Treatment Options
  • 27. Prescribing Trends
  • 28. Unmet Needs in HR+/HER2- Breast Cancer

EPIDEMIOLOGY: HER+/HER2- BREAST CANCER

  • 29. Executive Summary
  • 30. Disease Background
  • 31. Sources and Methodology
  • 32. Forecast
  • 33. Epidemiologist Insight
  • 34. Strengths and Limitations

MARKETED DRUGS: HR+/HER2- BREAST CANCER

  • 35. Executive Summary
  • 36. Product Overview
  • 37. Product profile: Afinitor
  • 38. Product profile: Avastin
  • 39. Product profile: Faslodex
  • 40. Product profile: Halaven
  • 41. Product profile: Ibrance
  • 42. Product profile: Ixempra

PIPELINE: HR+/HER2- BREAST CANCER

  • 43. Executive Summary
  • 44. Clinical Pipeline Overview
  • 45. Target Product Profile
  • 46. Product profile (late stage): Lynparza
  • 47. Product profile (late stage): abemaciclib
  • 48. Product profile (late stage): alpelisib
  • 49. Product profile (late stage): buparlisib
  • 50. Product profile (late stage): entinostat
  • 51. Product profile (late stage): niraparib
  • 52. Product profile (late stage): ribociclib
  • 53. Product profile (late stage): talazoparib
  • 54. Product profile (late stage): taselisib
  • 55. Product profile (late stage): veliparib
Back to Top